Development and Testing of Novel Contrast Agents for Diagnostic Imaging

点击翻译按钮获取中文摘要

Demand for diagnostic imaging in the Australian healthcare system is growing at over 5% per annum. To facilitate imaging, Australia imports radiographic contrast media costing in excess of $50 million every year. Existing iodine-based agents are not ideal for X-ray absorption in current CT scanners and also cause moderate to severe allergic reaction in around 5% of all patients, sometimes with fatal results. New radiographic media, which give enhanced contrast and provide greater patient comfort and safety are essential. Even a small fraction of the international market would generate millions of dollars in income, support growth and expertise in Imaging Technologies, and provide new markets for Australian mining of rare earth and bismuth metals.